Pharmacological inhibition of CD24/P-selectin signaling with PSI-697 showed promise for treating tumorgenic and metastatic PCA in our models and lay the foundation for further studies interrogating the therapeutic efficacy of PSI-697 for metastatic PCA (Fig. 7m). This evidence concerns the gene SELP and posterior cortical atrophy.